The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.

Gang YeJoseph P GallantChristopher MasseyKe ShiWanbo TaiJian ZhengAbby E OdleMolly A VickersJian ShangYushun WanAleksandra DrelichKempaiah R KempaiahVivian TatStanley PerlmanLanying DuChien-Te TsengHideki AiharaAaron M LeBeauFang Li

Published in: bioRxiv : the preprint server for biology (2020)

Potent and low-cost Nanosota-1 drugs block SARS-CoV-2 infections both in vitro and in vivo and act both preventively and therapeutically.

Keyphrases

sars cov
low cost
respiratory syndrome coronavirus
anti inflammatory
coronavirus disease